Related Attributes
Product details
Obeticholic Acid, also known as 6-ethyl goosenodeoxycholic acid, is a novel derivative of goosenodeoxycholic acid (CDCA) in human primary bile acids and a natural ligand of farnesate derivative X receptor (FXR). Obecholic acid is a farnesol X receptor agonist, which indirectly inhibits cytochrome 7A1 (CYP7A1) gene expression by activating farnesol X receptor. Because CYP7A1 is a rate-limiting enzyme for cholic acid biosynthesis, obecholic acid can inhibit cholic acid synthesis and is used in the treatment of primary biliary cirrhosis and non-alcoholic fatty liver disease.
Uses of Obeticholic Acid.
Obeccholic acid tablets can inhibit the synthesis of cholic acid, promote bile secretion and reduce portal hypertension, and can play a role in the treatment of primary biliary cirrhosis, non-alcoholic fatty liver, primary sclerosing cholangitis and other diseases when prescribed by doctors.
Obecholic acid tablet is a farnitol receptor agonist, which can indirectly inhibit the expression of cytochrome gene, thus inhibiting the synthesis of cholic acid, promoting bile secretion and reducing portal hypertension. Obeccholic acid tablets are often used to treat primary biliary cirrhosis, and can also be used to treat nonalcoholic fatty liver and primary sclerosing cholangitis. This product can be used alone or in combination with ursodeoxycholic acid, but patients with complete intestinal obstruction should contraindicate this product. The therapeutic effect of obecholic acid tablets is good, but some people will have adverse reactions after application, common adverse reactions include diarrhea, nausea, vomiting, abdominal pain and so on. However, these symptoms are usually temporary and usually resolve on their own after stopping the drug.
During the use of aubecholic acid tablets, regular follow-up visits should be made with a doctor to ensure the effectiveness and safety of treatment.
Pharmacological action of Obeticholic Acid.
PBC is a chronic cholestasis caused by bile duct dysplasia or bile acid metabolism disorder, which causes lipid dissolution of cell membrane, permeability change, cell content flow out, and eventually progress to liver fibrosis and cirrhosis. At present, ursodeoxycholic acid (URsodeoxycholic acid) is the main drug used in clinical treatment of PBC. Ursodeoxycholic acid stimulates hepatobiliary secretion through intracellular signaling molecule mitogen-activated protein kinase (MAPK) pathway, and protects epithelial cells from bile acid destruction.
Product Method of Bulk Obeticholic Acid Powder.
Why choose us?
HRK Factory
About Shipping
Pharmaceutical Intermediate manufacturers
©2022 Xi'an Henrikang Biotech Co., Ltd.,